Package Leaflet: Information for theuser
Darunavir Krka 400 mg film-coated tabletsEFG
Darunavir Krka 800 mg film-coated tabletsEFG
darunavir
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of theleaflet
What is DarunavirKrka?
Darunavir Krka contains the active substance darunavir. Darunavir Krka is an antiretroviral medicine used to treat infection by the Human Immunodeficiency Virus (HIV). It belongs to a group of medicines called protease inhibitors. Darunavir Krka reduces the amount of HIV in your body. This improves your immune system and reduces the risk of diseases associated with HIV infection.
What is itused for?
Darunavir Krka 400 mg and 800 mg tablets are used to treat adults and children (from 3 years of age and at least 40 kg body weight) infected with HIV:
Darunavir Krka must be taken with a low dose of ritonavir and other HIV medicines. Your doctor will prescribe the most suitable medicine combination for you.
Do not take DarunavirKrka
Do not take Darunavir Krka with any of the following medicines:
If you are taking any of these medicines, consult your doctor to change to another medicine.
Medicine | Purpose of the medicine |
Avanafil | treatment of erectile dysfunction |
Astemizoleor terfenadine | treatment of allergy symptoms |
Triazolamand midazolam taken by mouth | to help you sleep and/or relieve anxiety |
Cisapride | treatment of stomach problems |
Colchicine(if you have kidney and/or liver problems) | treatment of gout or familial Mediterranean fever |
Lurasidone, pimozide, quetiapineor sertindole | treatment of psychiatric problems |
Alkaloids of the ergot fungussuch as ergotamine, dihydroergotamine, ergometrineand methylergonovine | treatment of migraine headaches |
Amiodarone, bepridil, dronedarone, quinidine, ranolazine | treatment of certain heart problems, for example arrhythmias |
Lovastatin, simvastatin and lomitapide | to lower cholesterol levels |
Rifampicin | treatment of certain infections such as tuberculosis |
The combination of lopinavir/ritonavir | this HIV medicine belongs to the same class as Darunavir Krka |
Elbasvir/grazoprevir | to treat hepatitis C infection |
Alfuzosin | treatment of enlarged prostate |
Sildenafil | treatment of high blood pressure in the pulmonary circulation |
Ticagrelor | to help stop platelet aggregation during treatment in patients with a history of heart attack |
Do not take Darunavir Krka with products containing St. John's Wort (Hypericum perforatum).
Warnings and precautions
Consult your doctor, pharmacist or nurse before you start taking Darunavir Krka.
Darunavir Krka does not cure HIV infection. While you are taking this medicine, you may still develop infections or other illnesses associated with HIV infection. Keep in regular contact with your doctor.
People taking Darunavir Krka may develop skin rash. It is not common for the rash to be severe or potentially life-threatening. However, if you develop a rash, please consult your doctor.
Patients taking Darunavir Krka and raltegravir (for HIV infection) may be more likely to develop rash (usually mild or moderate) than patients taking either of these medicines separately.
Tell your doctor about your situation BEFORE and DURING treatment
Make sure you check the following points and tell your doctor if any of them apply to you.
Elderly population
Darunavir Krka has only been used in a limited number of patients aged 65 years or older. If you belong to this age group, please consult your doctor to see if you can use Darunavir Krka.
Children andadolescents
Darunavir Krka 400 mg and 800 mg tablets must not be used in children under 3 years of age or weighing less than 40 kg.
Taking Darunavir Krka with othermedicines
Tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines.
Some medicines must not be takenwith Darunavir Krka. The list can be found under the heading “Do not take Darunavir Krka with any of the following medicines:”
In most cases, Darunavir Krka can be taken with HIV medicines from other classes [e.g., NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists, and fusion inhibitors]. Darunavir Krka has not been tested with cobicistat or ritonavir and all protease inhibitors (PIs) and must not be used with other HIV protease inhibitors. In some cases, it may be necessary to change the dose of the other medicines. Therefore, if you are taking other anti-HIV medicines, always consult your doctor and follow their instructions carefully on which medicines can be combined.
The following products may reduce the effectiveness of Darunavir Krka. Tell your doctor if you are taking:
Darunavir Krka may also affect the action of other medicines. Tell your doctor if you are taking:
This is nota complete list of medicines. Tell your doctor about allthe medicines you are taking.
Taking Darunavir Krka with food anddrinks
See section 3 “How to take Darunavir Krka.”
Pregnancy andbreast-feeding
Tell your doctor immediately if you are pregnant, plan to become pregnant, or are breast-feeding. Pregnant or breast-feeding women must not take Darunavir Krka with ritonavir unless their doctor has specifically told them to do so. Pregnant or breast-feeding women must not take Darunavir Krka with cobicistat.
It is recommended that women infected with HIV do not breast-feed their babies because there is a possibility that the babies could become infected with HIV through their breast milk, and because of the unknown effects of the medicine on the babies.
Driving and usingmachines
Do not drive or use machines if you feel dizzy after taking Darunavir Krka.
Follow the administration instructions for the medicine indicated by this prospectus or by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse.
Even if you feel better, do not stop taking Darunavir Krka or ritonavir without consulting your doctor.
Once treatment has started, the dose or form of the dose should not be changed, nor should treatment be interrupted without consulting a doctor.
Darunavir Krka 400 mg and 800 mg tablets should only be used to achieve a daily dose of 800 mg.
This product is only available as film-coated tablets and is therefore not suitable for patients who cannot swallow tablets whole, such as young children. For use in these patients, the most suitable formulations containing darunavir should be checked to determine their availability.
Dose for adults who have not taken antiretroviral medications before (to be determined by your doctor)
The usual dose of Darunavir Krka is 800 mg daily (2 tablets containing 400 mg of Darunavir Krka each or 1 tablet containing 800 mg of Darunavir Krka).
You must take Darunavir Krka every day and always in combination with 100 mg of ritonavir and with food. Darunavir Krka does not work properly without ritonavir or without food. You must eat or have a snack 30 minutes before taking Darunavir Krka and ritonavir. The type of food does not matter. Even if you feel better, do not suspend treatment with Darunavir Krka and ritonavir without consulting your doctor.
Instructions for adults
Dose for adults who have taken antiretroviral medications before (to be determined by your doctor)
You may require a different dose of Darunavir Krka that cannot be administered with 400 mg or 800 mg tablets. There are other formulations of Darunavir Krka available.
The dose is:
Or
Please talk to your doctor to find out what dose is correct for you.
Dose for children from 3 years of age, with at least 40 kg of weight, who have not taken antiretroviral medications before (to be determined by your doctor in this case)
Dose for children from 3 years of age, with at least 40 kg of weight, who have taken antiretroviral medications before (to be determined by your doctor in this case)
The dose is:
Or
Please talk to your doctor to find out what dose is correct for you.
Instructions for children from 3 years of age, with at least 40 kg of weight
If you take more Darunavir Krka than you should
Inform your doctor or pharmacist immediately.
If you forget to take Darunavir Krka
If you realize within 12 hours, take the missed dose immediately. Always with ritonavir and with food. If you realize after 12 hours, skip that dose and make the next dose as usual.
Do not take a double dose to make up for missed doses.
Do not stop taking Darunavir Krka without talking to your doctor first
HIV medications can make you feel better. Even if you feel better, do not stop taking Darunavir Krka. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV therapy, there may be an increase in weight, blood lipid levels, and blood glucose levels. This is partly related to restored health and lifestyle, and in the case of blood lipids, sometimes to the HIV medications themselves. Your doctor will evaluate these changes.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Tell your doctor if you develop any of the following side effects.
There have been reports of liver problems that can occasionally be severe. Your doctor will perform a blood test before you start treatment with Darunavir Krka. If you have a chronic infection caused by hepatitis B or C, your doctor will frequently check your blood tests, as there is a higher likelihood of developing liver problems. Talk to your doctor about the signs and symptoms of liver problems. These can include yellowing of the skin and the whites of the eyes, darkening (tea color) of the urine, pale stools (bowel movements), nausea, vomiting, loss of appetite, or pain, discomfort, or tenderness in the right side below the ribs.
Skin rash (more frequent when used in combination with raltegravir), itching. The skin rash is usually mild to moderate. A skin rash can also be a symptom of a rare and serious situation. Therefore, it is essential to talk to your doctor if you have a rash. Your doctor will advise you on how to control the symptoms or if you should stop taking Darunavir Krka.
Other serious side effects were diabetes (frequent) and pancreatitis (uncommon).
Very common side effects (may affect more than 1 in 10 patients)
Common side effects (may affect up to 1 in 10 patients)
Uncommon side effects (may affect up to 1 in 100 patients)
eczema, excessive sweating, night sweats, hair loss, acne, scaly skin, nail discoloration
Rare side effects (may affect up to 1 in 1,000 patients)
Some side effects are typical of HIV medications that belong to the same family as Darunavir Krka. These are:
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the box and bottle, after EXP. The expiration date refers to the last day of the month indicated.
Keep the bottle tightly closed to protect it from moisture.
Validity period after first opening: 3 months
Medications should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any medication you no longer need. This will help protect the environment.
Composition of Darunavir Krka
Appearance of Darunavir Krka and package contents
The 400 mg Darunavir Krka tablets are:
Yellowish-brown, oval, biconvex film-coated tablets (tablets), marked with S1 on one side.
Tablet size: 17 x 8.5 mm.
The 800 mg Darunavir Krka tablets are:
Reddish-brown, oval, biconvex film-coated tablets (tablets), marked with S3 on one side.
Tablet size: 20 x 10 mm.
Darunavir Krka 400 mg film-coated tablets are available in bottles containing 30 tablets (1 bottle with 30 tablets), 60 tablets (2 bottles, each with 30 tablets), 90 tablets (3 bottles, each with 30 tablets), and 180 tablets (6 bottles, each with 30 tablets) in a box.
Darunavir Krka 800 mg film-coated tablets are available in bottles containing 30 tablets (1 bottle with 30 tablets), 60 tablets (2 bottles, each with 30 tablets), and 90 tablets (3 bottles, each with 30 tablets) in a box.
Not all pack sizes may be marketed.
Marketing authorization holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium KRKA Belgium, SA. Tel: +32 (0) 487 50 73 62 | Lithuania UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Bulgaria KRKA Bulgaria EOOD Tel: + 359 (02) 962 34 50 | Luxembourg KRKA Belgium, SA. Tel: +32 (0) 487 50 73 62 (BE) |
Czech Republic KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Hungary KRKA Magyarország Kereskedelmi Kft. Tel: + 36 (1) 355 8490 |
Denmark KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) | Malta
Tel: + 356 21 445 885 |
Germany TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 | Netherlands KRKA Belgium, SA. Tel: +32 (0) 487 50 73 62 (BE) |
Estonia KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 | Norway KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Greece QUALIA PHARMA S.A. Tel: +30 210 6256177 | Austria KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
Spain KRKA Farmacéutica, S.L. Tel: + 34 911 61 03 81 | Poland KRKA-POLSKA Sp. z o.o. Tel: + 48 (0)22 573 7500 |
France KRKA France Eurl Tel: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal, Lda. Tel: + 351 (0)21 46 43 650 |
Croatia KRKA - FARMA d.o.o. Tel: + 385 1 6312 100 | Romania KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 293 91 80 | Slovenia KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Iceland LYFIS ehf. Tel: + 354 534 3500 | Slovakia KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italy KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Finland KRKA Finland Oy Tel: +358 20 754 5330 |
Cyprus Kipa Pharmacal Ltd. Tel: + 357 24 651 882 | Sweden KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvia KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom Consilient Health (UK) Ltd. Tel: +44 (0)203 751 1888 |
This prospectus was last revised
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.